Enlivex Therapeutics Ltd logo

Enlivex Therapeutics Ltd

XTAE:ENLV (Israel)  
₪ 5.54 (-1.32%) Sep 23
At Loss
P/B:
1.08
Market Cap:
₪ 125.08M ($ 33.30M)
Enterprise V:
₪ 25.95M ($ 6.91M)
Volume:
20.87K
Avg Vol (2M):
24.27K
Trade In:
Volume:
20.87K
At Loss

Business Description

Description
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
Name Current Vs Industry Vs History
Cash-To-Debt 31.07
Equity-to-Asset 0.9
Debt-to-Equity 0.03
Debt-to-EBITDA -0.05
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 49.05
9-Day RSI 57.7
14-Day RSI 59.04
6-1 Month Momentum % -65.74
12-1 Month Momentum % -32.35

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 10.06
Quick Ratio 10.06
Cash Ratio 9.13

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -8.4
Shareholder Yield % -6.26
Name Current Vs Industry Vs History
ROE % -66.11
ROA % -55.81
ROIC % -174.14
3-Year ROIIC % -684.15
ROC (Joel Greenblatt) % -259.41
ROCE % -52.43